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Purpose: To evaluate whether inhibition of phosphorylated Akt (pAkt) would reduce or prevent posterior capsule
opacification (PCO) in an ex vivo canine lens capsule model.
Methods: Normal and cataractous lenses (n=6) were evaluated for pAkt via immunohistochemistry and immunoblotting.
Primary cultures of lens epithelial cells (LEC) were exposed to ultraviolet light (UV) to induce pAkt. Cultures were then
incubated in 0, 2.5, 5, or 10 µM (n=6) of a novel Akt inhibitor (AR-12) for either 8 or 24 h. Cultures were harvested and
pAkt expression and telomerase activity examined by immunoblotting and telomeric repeat amplification protocol
(TRAP)-enzyme linked immunosorbent assay (ELISA), respectively. Lens capsules were harvested post-sham cataract
surgery and exposed to 0, 2.5, 5, 7.5, or 10 μM (n=8) of AR-12 for a total of 14 days treatment. Additional lens capsules
(n=6) were exposed to 10 μM of AR-12 for 1 week followed by media alone for 1 week; or exposed to media alone for 1
week followed by 10 μM of AR-12 for 1 week. Histopathology and immunohistochemical staining were performed to
evaluate PCO formation. Analysis of telomerase activity on the lens capsules was performed by TRAP-ELISA.
Results: pAkt protein expression was increased in clinical samples of canine cataracts compared to normal lenses.
Following exposure to UV, cultures of LEC significantly (p<0.05) increased expression of pAkt and telomerase activity.
Treatment with AR-12 for both 8 and 24 h following UV irradiation significantly (p<0.01) decreased pAkt expression.
When UV-exposed LEC were allowed to recover in the presence of either 5.0 or 10.0 µM AR-12, there was a significant
(p<0.05) decrease in telomerase activity. In the ex vivo model of PCO, within the region of the capsulorhexis, PCO
inhibition was maximally achieved with 10 μM of AR-12. A significant decrease in LEC was noted on the posterior
capsules containing 5.0, 7.5, and 10 μM AR-12 compared to the control capsules (p<0.01). Telomerase activity decreased
in a dose-dependent manner. One week of treatment with 10 μM AR-12, immediately following capsule excision, was
sufficient to inhibit PCO formation, while a delay in exposure to AR-12 after 1 week of media incubation alone did not
prevent PCO formation.
Conclusions: pAkt is known to have roles in cell survival, proliferation, and migration, and this study suggests its
inhibition immediately following cataract surgery may be a useful approach to prevent PCO.
Phacoemulsification  extracapsular  cataract  extraction
with intraocular lens (IOL) implantation is the most common
ophthalmic surgical procedure performed today in human and
veterinary  ophthalmology  [1,2].  Though  current  cataract
surgery  with  IOL  placement  carries  a  greater  than  95%
success  rate,  the  most  common  long-term  postoperative
complication in both humans and dogs is posterior capsule
opacification  (PCO)  [1,2].  Postoperatively,  the  primary
response of the remaining lens epithelial cells (LEC) is to
proliferate  and  undergo  epithelial-mesenchymal  transition
(EMT), that is, change from normal cuboidal epithelial cells
into  spindle  shaped  fibroblast-like  cells  that  expresses  α-
smooth muscle actin [3,4]. The average time to significant
clinical PCO in humans is 26 months postoperatively, with a
range of three months to five years [5]. In humans, PCO occurs
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in  30%–50%  of  all  surgical  patients  up  to  5  years  post-
operatively,  depending  on  age,  location,  and  type  of
intraocular implant, while the incidence of PCO in dogs is
100% by one year post-operatively [5-9].
Telomerase is a ribonucleoprotein complex that primarily
maintains telomeres but can also heal broken chromosomes
and has anti-apoptotic functions [10,11]. Telomerase is absent
from  most  normal  somatic  cells,  hence  their  finite
proliferative potential, but is found in germline and stem cells,
the majority of cancers, and LEC [12-18]. Telomerase activity
is  almost  threefold  higher  in  cataractous  LEC  and
significantly higher in lens capsules with PCO than in normal
LEC [18]. We have found that canine and human lens capsules
with PCO formation have high telomerase activity which may
contribute to lenticular EMT by giving the cells unlimited
proliferative capability [19].
Breakdown  in  the  blood:aqueous  barrier  following
cataract surgery can increase the expression of growth factors
and cytokines in the aqueous humor, promoting EMT [20].
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2202Many of the mitogens found in the aqueous humor, such as
transforming growth factor-β (TGF-β) and platelet-derived
growth factor (PDGF), can induce lenticular EMT through the
Akt  pathway  [21,22].  Previously,  we  have  shown  that
phorphylated Akt (pAkt) interacts with and phosphorylates
telomerase in canine LEC that have undergone EMT, but not
in normal canine LEC [23,24]. It is possible that induction of
pAkt results in increased lenticular telomerase activity, thus
promoting PCO formation. Because telomerase activity is
only minimally expressed within the eye [18,25], the use of
acute pAkt inhibition in the lens capsule following cataract
surgery to prevent telomerase activation may be a potential
strategy to prevent or reduce PCO. The aim of this study was
to assess expression of pAkt in LEC undergoing EMT and to
determine the effect of inhibiting signal transduction through
Akt on PCO formation in an ex vivo canine lens capsule
explant model.
In  this  study,  the  pharmacological  inhibition  of  pAkt
signaling  was  achieved  through  the  use  of  AR-12  [26]
(formerly OSU-03012; Arno Therapeutics, Inc., Parsippany,
NJ), a novel small molecule inhibitor of phosphoinositide-
dependent protein kinase-1 (PDK-1), the immediate upstream
activating kinase of Akt, that is currently being evaluated in
Phase I clinical trials in cancer patients. To evaluate the effect
of  AR-12  on  LEC,  primary  cultures  were  stressed  with
ultraviolet (UV) irradiation and allowed to recover in the
presence or absence of AR-12 before pAkt expression and
telomerase activity were assessed [27]. To evaluate the effect
of AR-12 in a PCO model, telomerase activity was measured
and  immunoreactivity  of  pAkt  and  telomerase  reverse
transcriptase (TERT) were determined as their expression
have been shown to correlate with telomerase activity [19,
28-30]. Integrin-linked kinase (ILK), α-smooth muscle actin
(αSMA), and proliferating cell nuclear antigen (PCNA) were
assessed  as  indicators  of  EMT,  cell  migration,  and
proliferation of LEC, respectively [4,31,32]. Expression of
cleaved caspase-3 was used to evaluate whether cells were
undergoing apoptosis in our ex vivo PCO model [33].
METHODS
Samples: Normal eyes were obtained by enucleation from
dogs in good general health that were humanely euthanized at
a local animal shelter for population control purposes. The
eyes were examined with a focal light source and deemed free
of corneal disease, cataract, or other anterior segment disease.
All dogs used in this study were estimated to be between 1
and 8 years of age, based on dentition and thickness of the
anterior lens capsule. Globes were collected within one hour
of death and placed in dilute betadine solution, then rinsed and
immersed in 1× phosphate buffered saline solution (PBS, pH
7.2) until dissection. Excess conjunctiva and Tenon’s capsule
were excised from the perilimbal region, and a stab incision
was made into the anterior chamber 1 mm posterior to the
limbus.  Anterior  lens  capsules  with  adherent  LEC  were
excised from each lens for protein extraction and immediately
frozen and stored at −70 °C until extraction. Whole lenses and
anterior lens capsules with adherent LEC were also fixed in
10%  neutral-buffered  formalin  for  immunohistochemical
staining.
Cataractous lens capsules were obtained from clinically
normal  dogs  undergoing  elective  phacoemulsification
cataract  surgery  at  The  Ohio  State  University  College  of
Veterinary Medicine. These capsules consisted of mature and
hypermature cataracts that were considered either diabetic or
non-diabetic in their etiology. These canine cataracts almost
universally have LEC that have undergone EMT and posterior
migration onto the posterior capsule [32]. Samples chosen for
this study had obvious subcapsular plaques or diffuse LEC
proliferation onto the posterior lens, evident at the time of
surgery. Patients with only nuclear cataract were not included
in  this  study.  Cataractous  samples  were  obtained  by
continuous curvilinear capsulorhexis and either immediately
placed in 10% neutral-buffered formalin or snap frozen and
stored at −70 °C until protein extraction.
All  fixed  samples  were  paraffin  embedded,  sections,
stained  with  hematoxyline  and  eosin  (H&E),  and  then
examined  by  light  microscopy.  For  immunohistochemical
staining,  samples  were  sectioned  onto  charged  slides
(ProbeOn Plus; Fisher Scientific, Pittsburg, PA).
Primary cultures: Anterior lens capsules with adherent LEC
were obtained via dissection from normal canine eyes, as
described  above.  Following  dissection  capsules  were
incubated in trypsin (0.25% trypsin and 1× EDTA; Gibco,
Carlsbad,  CA)  for  5  min  at  37  °C.  After  incubation,  the
solution and lens capsule were centrifuged for 2 min at 0.3×
g. Fluid was decanted and supplemented DMEM (containing
10%  fetal  bovine  serum  and  1%  antibiotic/antimycotic
[Gibco]) was then added. The solution, including the lens
capsule,  was  transferred  to  a  laminin-coated  culture  flask
(Beckton-Dickinson, Franklin Lakes, NJ) an incubated in a
humidified incubator at 37 °C and 5% CO2. LEC were grown
until 90% confluence before re-plating.
Irradiation and treatment with AR-12: Cultures of primary
LEC were washed and covered with PBS, then exposed to UV
irradiation. The UV source was from Philips TL20 W/12 RS
UV-B lamps (American Ultraviolet Company, Murray Hill,
NJ). These lights emit wavelengths of light between 280 and
400 nm, with a peak at 313 nm. The lamps emit approximately
60%  UV-B  and  40%  UV-A  [34].  Radiation  was  filtered
through Kodacel (Eastman Kodak, Rochester, NY), to remove
wavelengths below 280 nm [35]. Based on preliminary and
previously published data, the cells were irradiated with either
0 or 600 J/m2, which can induce expression of both pAkt and
telomerase [23,27]. Following exposure, PBS was removed
and serum-free DMEM containing AR-12 was placed on the
cells. The doses of AR-12 used were 0 (vehicle only), 2.5, 5.0,
and 10.0 µM (n=6). Cells were collected 8 or 24 h after
irradiation for immunoblot and telomerase activity analysis.
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lens capsule dissection was performed as described previously
[36-38]. Residual cortical material was removed gently by
manual irrigation/aspiration with a coaxial cannula, but no
effort was made to polish the anterior or posterior lens capsule.
The lens capsule was excised from the zonular and vitreal
attachments  and  pinned  to  a  polymethylmethacrylate
(PMMA) Petri dish also as previously described [38]. All
capsules  were  cultured  in  a  total  of  5.0  ml  of  DMEM
containing 1% antibiotic and antimycotic (Gibco).
Treatment groups: Each group contained 8 lens capsules and
5 groups were treated with 0.0, 2.5, 5.0, 7.5, or 10.0 μM
AR-12,  which  was  synthesized  in-house  as  described
previously [26]. The lens capsules were incubated at 37 °C in
5% CO2, and the culture medium replaced every 3 days for 14
days.  Morphologic  observations  were  made  with  phase-
contrast microscopy. Two additional groups of lens capsules
were harvested (n=6 per group). One group was exposed to
DMEM supplemented with 10.0 μM AR-12 for the first week
of incubation, followed by a week of DMEM alone. The
second group was exposed to DMEM alone for the first week
of  incubation,  followed  by  DMEM  supplemented  with
10.0 μM AR-12 for the second week of incubation. After 2
weeks, all lens capsules were fixed in 10% neutral-buffered
formalin, embedded in paraffin, and sectioned.
Telomeric repeat amplification protocol (TRAP): The TRAP
assay, modified by the Intergen Company (Norcross, GA), is
an extension of the original method [18]. In the first step,
telomerase,  if  present  in  the  protein  lysate,  adds  several
telomeric repeats onto the 3′ end of a biotinylated telomerase
substrate  oligonucleotide  (b-TS).  In  the  second  step,  the
extended  products  are  amplified  by  PCR  using  Taq
polymerase,  the  b-TS  and  RP  (reverse)  primers,  and  a
deoxynucleotide  mix  containing  dCTP  labeled  with
dinitrophenol, generating a ladder of products with six base
increments, starting at 50 nucleotides (Chemicon, Temecula,
CA). Briefly, for our studies, a master mix was prepared with
5× TRAP Reaction mix, Taq polymerase (Panvera Takara,
Carlsbad, CA), and RNase-free water. One µg of protein was
added to the Master mix for a final volume of 50 µl; all set-
up steps were performed on ice. Primer extension was then
performed at 30 °C for 30 min, followed by 33 cycles of
amplification as follows: denaturation for 30 s at 94 °C and
annealing for 30 s at 53 °C. Samples were held at 4 °C until
detection  using  hybridization  and  ELISA  (absorbance
measured at 450 nm with reference wavelength of 690 nm)
following manufacturer’s protocol, and electrophoresis on a
10% nondenaturing polyacrylamide gel that was subsequently
stained  with  SYBR  gold  (1:10,000;  Molecular  Probes,
Carlsbad,  CA).  By  comparing  the  PAGE  gel  method  of
evaluating TRAP results with the ELISA methods, we have
set 0.100 units as the lowest amount of detectable telomerase
activity.
Histological  and  immunohistological  evaluation:  Routine
H&E staining was performed on ex vivo capsules to evaluate
cell morphology and cell counts. All LEC adhered to the
capsule  were  manually  counted  in  10  H&E  sections  per
capsule. The quantitative analysis was performed on sections
taken as close as possible to the capsule midline. Cell counts
were performed by two independent observers.
Immunohistochemical  staining  was  performed  as
previously  described  [38]  using  antibodies  against  TERT
(1:350;  Calbiochem,  San  Diego  CA),  pAkt  (1:350;  Santa
Cruz, Santa Cruz, CA), cleaved caspase-3 (1:20; Oncogene,
San Diego CA), ILK (1:200; Stressgen, San Diego CA), α-
SMA (1:100; Spring Bioscience, Freemont CA), and PCNA
(1:200; DAKO Corp., Carpinteria CA). Secondary antibodies
included,  as  appropriate,  anti-goat  (Vector  Laboratories,
Burlingame CA), anti-rabbit (Biogenex Super Sensitive Link;
Biogenex,  San  Ramon  CA),  and  anti-mouse  (Vector
Laboratories)  antibodies.  DAKO  Antibody  Diluent  with
Background  Reducing  Components  (DAKO)  was  used  to
dilute antibodies. Immunostaining was visualized with either
diaminobenzidine tetrahydrochloride (DAB, DAKO) applied
for 3 min at room temperature in the dark or with Vector
NovaRED (Vector Laboratories) applied for 5 min at room
temperature.
Appropriate  positive  and  negative  controls  were
performed  with  each  experiment.  Canine  squamous  cell
carcinomas were used as a positive control for TERT, pAkt,
α-SMA, ILK, and caspase-3. A normal canine lymph node
was used as a positive control for PCNA. Negative controls
omitted the primary antibody.
Immunobloting: Whole cell protein was extracted from frozen
positive controls, normal canine anterior lens capsules, and
anterior capsulotomy samples from clinical canine cataracts
using 1× CHAPs lysis buffer (Chemicon, Temecula, CA) in
accordance with the manufacturer’s instructions with minor
adaptations for our tissue as previously described [19]. Protein
concentration was quantified using the Bradford protein assay
(Bio-Rad, Hercules, CA).
Samples  were  denatured  (95  °C,  3  min)  in  modified
sodium dodecyl sulfate (SDS) sample loading buffer, and
protein  (15  µg)  was  separated  by  SDS/PAGE  (10%
acrylamide, v/v) at 150 V for approximately 1.5 h. After
electrophoresis, proteins were transferred to a nitrocellulose
membrane at 300 mA for 1.5 h. Nonspecific binding was
blocked  by  incubating  the  membrane  for  5  h  at  room
temperature in 5% nonfat dry milk diluted in 1× Tris-buffered
saline containing 0.1% Tween-20 (TBST), After blocking,
membranes  were  incubated  overnight  with  pAkt  (Cell
Signaling, Danvers, MA), diluted 1:500 in blocking buffer.
The membrane was then washed extensively with 1× TBST,
and secondary antibody (donkey anti-rabbit, Santa Cruz) was
added  in  blocking  buffer  (1:8,000)  for  1  h  at  room
temperature. Protein was detected using the Pierce (Rockford,
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(Pierce) and the technique was repeated using anti-β-actin
antibody (1:5,000; Sigma-Aldrich, St. Louis, MO). Kodak 1D
Image Analysis Software (Kodak Molecular Imaging, New
Haven, CT) was used to obtain densitometry readings for all
western blots.
Statistical analysis: All statistical analysis was performed
with Prism version 4.0 software (GraphPad Software Inc. San
Diego, CA). All data was analyzed using one-way ANOVA
(ANOVA) with Tukey’s post-test. The capsule cell counts
were evaluated with a non-paired Students’ t-test. The level
for  statistical  significance  was  set  at  p<0.05  for  all
comparisons. All graphs were generated in Prism version 4
and display the mean and standard error of the mean (SEM),
represented by error bars.
RESULTS
pAkt expression in normal and cataractous lens epithelial
cells: As evaluated by immunohistochemisty, normal canine
LEC  had  minimal  to  no  detectable  pAkt  protein  present
(Figure  1A),  while  immunostaining  for  pAkt  was  strong
predominantly  in  the  cytoplasm  of  naturally  occurring
cataractous canine LEC (Figure 1B) and clinical samples of
canine PCO (Figure 1C). Western immunoblotting confirmed
that  LEC  from  clinical  cataract  samples  had  increased
expression of pAkt protein compared to normal LEC (Figure
1D). Samples from our ex vivo model of PCO formation
demonstrated  strong  expression  of  pAkt,  as  observed  by
western blot (Figure 1D).
Expression of pAkt and telomerase activity follow irradiation
and  AR-12  treatment:  Irradiation  of  LEC  significantly
induced expression of pAkt at both 8 (p<0.05; Figure 2A) and
24 (p<0.01; Figure 2B) h compared to controls, as observed
by western blot analysis. In the presence of AR-12, all doses
tested were capable of significantly (p<0.01) decreasing pAkt
expression in irradiated LEC compared to LEC that received
UV irradiation in the absence of AR-12 (Figure 2A,B). This
was observed at both 8 (Figure 2A) and 24 (Figure 2B) h. Cells
treated with AR-12 alone did not significantly alter pAkt
expression (Figure 2A,). As previously demonstrated [27],
when assessed by the TRAP assay, telomerase activity was
significantly (p<0.05) increased in LEC that were exposed to
irradiation and allowed to recover for 24 h (Figure 2C). When
UV-exposed LEC were allowed to recover in the presence of
either 5.0 or 10.0 µM AR-12, there was a significant (p<0.05)
decrease in telomerase activity compared to the cells that were
irradiated and received 0.0 µM AR-12 (Figure 2C).
Control ex vivo lens capsules: Immediately post-dissection,
lens capsules had visible LEC present on the anterior capsule
only. By 3 days post-dissection, untreated LEC had migrated
across the anterior and posterior lens capsules. By 7 days post-
dissection, LEC were present on the posterior capsule in the
central visual axis in most lens capsules, and all had reached
confluence by 14 days post-extraction (Figure 3A). The LEC
morphology was cuboidal to hexagonal and there was little
anisocytosis. Hematoxylin and eosin staining confirmed the
phase  contrast  findings  (Figure  3B).  At  2  weeks  post-
dissection, the control lens capsules contained confluent cells
on both the anterior and posterior capsules with focal areas of
LEC hyperplasia in the equatorial region.
AR-12 treated ex vivo lens capsules: All LECs in the lens
capsules treated with 2.5 μM AR-12 in DMEM displayed mild
intracellular vacuolization and anisocytosis. Some areas of
lens capsule contained sparse LEC, but confluence was visible
by 7 days after sham cataract surgery. Histopathologically,
LEC were flattened and visibly fewer in numbers compared
to control lens capsules (Figure 3C,D).
All lens capsules treated with 5 μM of AR-12 in DMEM
had areas devoid of LECs and confluence was not achieved
by 14 days after sham cataract surgery. LEC were severely
vacuolated and varied in size and shape. Histologically, most
areas of the anterior and posterior lens capsules were devoid
of  LEC;  cells,  as  observed  with  phase  contrast,  indicated
abnormal morphology and vacuolization (Figure 3E,F).
Neither lens capsule groups treated with 7.5 nor 10 μM
AR-12 in DMEM supported LEC migration and proliferation.
The lens capsules contained minimal numbers of LEC on
phase contrast evaluation of 7.5 μM-treated capsules, and
capsules were devoid of all LEC on phase contrast evaluation
of 10 μM AR-12-treated. These findings were confirmed with
histopathology (Figure 3G-J).
Effects of late Akt inhibition on LEC: Lens capsules treated
with DMEM only for 7 days, followed by 7 days of treatment
with 10 μM AR-12 in DMEM were grossly and histologically
similar to the control lens capsules. By 7 days post dissection,
confluence was attained across the entire posterior capsule in
most lens capsules (data not shown).
Effects of early Akt inhibition of LEC: Lens capsules treated
with 10 μM AR-12 in DMEM for 7 days, then treated with
compound-free  media  for  7  days  were  grossly  and
histologically  similar  to  those  lens  capsules  treated  with
10 μM AR-12 continuously for 14 days. The lens capsules
were devoid of all LEC on phase contrast evaluation (data not
shown).
Telomerase  activity:  All  capsules  with  LEC  present
underwent TRAP evaluation for the presence or absence of
telomerase  activity.  There  was  a  significant  decrease  in
telomerase activity in the AR-12 treated groups compared to
the untreated controls (Figure 4). Capsules in the 10 µM
treatment group did not undergo TRAP evaluation because
there were no LEC were present following 14 days of culture.
Lens epithelial cell counts: The posterior capsule LEC counts
of  the  5.0,  7.5,  and  10.0  uM  -treated  capsules  were
significantly lower than those of the control capsules (p<0.05
and p<0.01; Figure 5A). Similar results were obtained by two
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the  5.0  uM  AR-12  was  lower  than  those  of  the  control
capsules,  however,  this  was  not  a  significant  difference
(Figure 5B). The complete capsule LEC count of the 7.5 and
10.0 uM treated capsules were significantly lower than the
complete control capsule LEC counts (p<0.01 and p<0.001;
Figure 5B).
Immunohistochemical  staining  following  pAkt  inhibition:
Immunohistochemical staining of LEC in all lens capsules, in
all treatment groups, excluding 10 µM due to a lack of cells,
showed equivalent moderate immunoreactivity for ILK, α-
Figure 1. Expression of pAkt in normal
canine  LEC  and  in  LEC  undergoing
EMT. A: In normal LEC there is little to
no immunoreactivity, while LEC in B:
clinical cataracts and C: clinical samples
of  PCO,  show  marked  cytoplasmic
staining for pAkt. The scale bar is equal
to  30  µm.  D:  western  blot  analysis
demonstrates  increased  expression  of
pAkt protein in both cataractous LEC
and LEC in the ex vivo model of PCO
formation,  compared  to  normal  LEC.
The  ‘+’  indicates  a  canine  mast  cell
tumor  which  was  used  as  a  positive
control for pAkt expression.
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2206Figure  2.  Expression  of  pAkt  and
telomerase  activity  following  UV
irradiation  and  AR-12  treatment.  A:
pAkt  expression  in  LEC  8  h  after
treatment with AR-12 alone, UV and
vehicle, or UV and AR-12. There was a
significant increase in LEC pAkt protein
expression following UV irradiation in
the absence of AR-12 (light gray bars).
A  significant  decrease  in  pAkt  levels
was found in LEC that were irradiated
and allowed to recover in the presence
of  AR-12  (white  bars),  compared  to
LEC that were irradiated and allowed to
recover  in  the  absence  of  AR-12.
Treatment  with  AR-12  alone  did  not
impact  the  expression  of  pAkt  (dark
gray bars). B: pAkt expression in LEC
24 h after treatment with AR-12 alone,
UV  and  vehicle,  or  UV  and  AR-12.
There was a significant fold change in
pAkt  expression  in  LEC  that  were
irradiated and allowed to recover in the
absence  of  AR-12  (light  gray  bars).
pAkt  expression  was  significantly
reduced  when  LEC  were  allowed  to
recover from irradiation in the presence
of AR-12 (white bars). C: Telomerase
activity  in  LEC  24  h  after  treatment.
Telomerase  activity  was  significantly
increased  in  LEC  following  UV
exposure.  A  significant  decrease  in
telomerase activity was noted in LEC
that  were  irradiated  and  allowed  to
recover in the presence of 5.0 or 10.0
µM  AR-12  for  24  h.  Treatment  with
AR-12 alone did not alter telomerase
activity in LEC (* indicates p<0.05 and
** indicates p<0.01).
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2207Figure 3. AR-12 treatment in the ex vivo model of PCO following 14 days. A: Lens capsules treated with DMEM media and vehicle as viewed
by phase contrast microscopy (scale bar is equal to 20 µm); the cells are healthy and cuboidal to hexagonal in shape with very little anisocytosis.
B: Lens capsules treated with DMEM and vehicle (H&E, scale bar is equal to 30 µm); LEC are of normal morphology and present across the
anterior and posterior lens capsules. C: Lens capsules treated with 2.5µM AR-12 and viewed by phase contrast microscopy (scale bar is equal
to 20 µm); the cells are mostly cuboidal to hexagonal in shape but some vacuolation is present. D: Lens capsules treated with 2.5 µM AR-12
(H&E, scale bar is equal to 30 µm); LEC display anisocytosis and are fewer in number compared to control. E: Phase contrast photograph
(scale bar is equal to 20 µm) or F: H&E sectioning (scale bar is equal to 30 µm) of lens capsules treated with 5 µM AR-12; there is marked
vacuolation, cells lack normal morphology and there are areas of capsule devoid of epithelial cells. Lens capsules treated with 7.5 µM AR-12
as viewed by either G: phase contrast microscopy (scale bar is equal to 20 µm) or H: H&E sectioning (scale bar is equal to 50 µm) had no
normal LEC; few cells and cellular debris remains within the lens capsule and are adherent to the anterior or posterior lens capsules. I: Lens
capsules treated with 10 µM AR-12 and viewed by phase contrast microscopy (scale bar is equal to 20 µm); the lens capsule is devoid of LEC.
J: Lens capsules treated with 10 µM AR-12 (H&E, scale bar is equal to 30 µm); anterior and posterior lens capsules are without LEC.
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2208SMA,  and  PCNA  (data  not  shown).  There  was  positive
immunoreactivity for TERT and pAkt in all treatment groups,
but a subjective decrease in staining was observed in the
7.5 μM-treated groups, in comparison to untreated control, 2.5
and 5 μM-treated groups (Figure 6 and Figure 7). Caspase-3
immunoreactivity  was  variable,  but  increased  numbers  of
positive cells were seen in lens capsules treated with AR-12
concentrations at 5 μM and above (Figure 8).
DISCUSSION
PCO  is  the  most  common  post-operative  complication  of
human and canine cataract surgery [1,2,5-9]. Postoperatively,
the primary response of the remaining LEC is to undergo
EMT,  proliferate,  and  increase  production  of  aberrant
extracellular  matrix  proteins.  Additional  morphological
alterations in these LEC include cell elongation, organelle
loss, and nucleolar chromatin condensation [39]. It has been
shown that the anterior LECs in both rabbits and humans
initially  undergo  hyperplasia  and  transform  into  spindle-
shaped myofibroblasts [40,41] that, along with the LEC at the
lens equator, migrate posteriorly and abnormally occupy the
posterior capsule [5,42].
Multiple growth factors found within the aqueous humor
have been documented to play important roles in the induction
of PCO [20]. Evidence to implicate TGF-β in PCO formation
is  strong  and  supported  by  multiple  studies;  in  fact,
Figure  4.  Comparative  analysis  of
telomerase  activities  in  canine  lens
capsules treated with various doses of
AR-12. There is a significant decrease
in activity in all of the treatment groups
compared to the controls. (* indicates a
p<0.05; ** indicates a p<0.01).
Figure 5. Posterior and total lens capsule cell counts. A: The number of LEC present on the posterior capsule was significantly lower in the
groups treated with 5.0, 7.5, and 10.0 uM AR-12 than in control capsules (* is p<0.05; ** is p<0.01). B: The total number of LEC present
within the entire capsule was significantly lower in capsules treated with 7.5 and 10.0 uM AR-12 compared to the control capsules (* is p<0.01;
** is p<0.001).
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2209Wormstone et al. [22,43-45] found that acute exposure to
TGF-β could produce long-term changes in lens capsules.
There is substantial cross-talk between the TGF-β and PI3K/
Akt pathway, particularly during EMT [22,46]. Other growth
factors, such as PDGF, have previously been found to induce
and  regulate  LEC  proliferation  and  may  be  involved  in
modulation of cellular migration [47-50]. One recent study
has found that induction of the PDGF pathway in human LEC
resulted in a PI3K/Akt pathway dependent increase in cellular
migration [21]. It is likely that aqueous humor growth factors
such as TGF-β and PDGF, can induce expression of pAkt in
LEC resulting in PCO, particularly if there is breakdown of
the  blood:aqueous  barrier  postoperatively.  As  such,  the
involvement of the PI3K/Akt pathway in the formation of
PCO  is  potentially  important  in  designing  therapeutic
strategies to inhibit the formation of PCO.
Several pharmacologic agents have been tested to inhibit
PCO formation; however, to date, there are no reports on the
use of specific Akt inhibitors to prevent LEC migration and
proliferation. Research performed in our laboratory indicates
that use of celecoxib an ex vivo model, results in decreased
PCO formation [38]. Celecoxib is capable of inhibiting both
COX-2  and  Akt;  it  was  speculated  that  one  mechanism
celecoxib was effective in preventing in vitro PCO formation
was due to increased Akt regulated apoptosis [38]. In vitro and
postoperative  use  of  the  NSAID,  diclofenac,  has  been
associated with decreased PCO formation [51-53]. Diclofenac
enhanced apoptosis has been linked to Akt downregulation in
other cell types and may exert similar effects in LEC [54].
Alternate pharmacologic agents with no known Akt inhibiting
mechanisms have been used to prevent PCO formation in
vitro. Some examples include, seleno-cystamine coated IOLs
which have the potential to serve as an effective, longer lasting
means of preventing PCO, although in vivo trials are needed
[55]. Hypoosmolar and antimetabolites such as mitomycin,
daunomycin,  and  5-fluorouracil,  have  been  effective  in
inhibiting  PCO  in  vitro  through  LEC  lysis  [56-60].
Unfortunately, in vivo concentrations high enough to inhibit
LEC proliferation, whether as a single application or as a
sustained release, have resulted in toxic effects to the corneal
endothelial cells, iris, ciliary body and/or retina [61].
AR-12  is  a  novel  small  molecule  derived  from  the
chemical backbone of the COX-2 inhibitor, celecoxib. It is
devoid of COX-2 inhibitory activity [26]. In this study, we
have shown that AR-12 can induce LEC death when used at
various  concentrations  in  vitro  and  can  decrease  PCO
formation in the canine lens capsule explant model. There was
a positive correlation between concentration of AR-12 used
and LEC apoptosis, as determined by decreased cell viability
and increased caspase-3 expression in non-confluent LEC.
Figure 6. Immunohistochemistry for pAkt in canine lens capsules treated with AR-12 for 14 days. A: Untreated control capsules had strong
expression of pAkt; as the concentration of AR-12 increased, the expression of pAkt decreased. B: 2.5 µM AR-12; C: 5.0 µM AR-12; D: 7.5
µM AR-12. Scale bar in all images is equal to 30 µm.
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2210Because of this, we speculate that pAkt is critical to the initial
adhesion,  migration,  or  morphological  change  needed  for
LEC  to  undergo  EMT.  Additionally,  this  is  based  on  the
observation that exposure of the LEC for only one week with
AR-12  induced  apoptosis,  while  a  7-day  delay  in  AR-12
treatment failed to induce observable changes in experimental
PCO formation.
Shorter exposures of LEC to AR-12 were not tested to
determine the minimal treatment durations needed to induce
cell death. Normal cells that require adhesion to a basement
membrane will die by an apoptotic mechanism termed anoikis
shortly  after  they  lose  this  adhesion  unless  they  have
undergone transformation or are neoplastic [62]. PI3K/Akt
signaling is a critical pathway for anchorage-dependent cell
survival  and  growth  and  protects  cells  from  anoikis  by
inactivating key apoptotic proteins and enhancing anchorage-
independent cell cycle progression [62]. Anoikis is a plausible
mechanism by which LEC are dying in these experiments as
the LEC are visibly separating from the lens capsule and
dying.
Data  presented  here  demonstrates  that  AR-12  can
significantly inhibit telomerase activity in canine LEC; AR-12
also subjectively inhibited pAkt and TERT expression. We
cannot be certain that this effect is not a reflection of cell loss,
but  equal  protein  concentrations  are  used  in  testing  to
minimize this variable. This finding suggests that pAkt and
TERT may be necessary at an initial step for EMT to occur in
LEC during PCO and cataract formation.
To evaluate cellular changes in this model, ILK, α-SMA,
and PCNA were used as indicators of cell migration, EMT,
and proliferation of LEC [4,31,32]. Immunohistochemistry
for  α-SMA  and  PCNA  indicates  that  our  ex  vivo  model
accurately mimics the migration and proliferation of LEC
seen during in vivo PCO formation. ILK can influence a wide
range  of  cellular  processes  in  development  and  disease
(proliferation, migration, EMT) [4], and many of these effects
may be due to its activation of Akt and interaction with the
PI3K  pathway.  Transfection  of  LEC  with  ILK-expressing
constructs induces a morphologic change that resembles EMT
[4]. In support of this, LEC present in our ex vivo PCO model
were undergoing EMT and were positive for ILK expression.
In this study, we did not see any changes in expression of ILK
in capsules that were treated with AR-12. These findings
support the hypothesis that ILK is an upstream mediator of
Akt activation and not directly affected by inhibition of pAkt.
In  vivo  studies  using  inhibitors  of  Akt  signaling
perioperatively  to  control  PCO  formation  are  planned  in
animal models. Previous use of chemical inhibitors of PCO
Figure 7. Immunohistochemistry for TERT in canine lens capsules treated with AR-12 for 14 days. A: Untreated control capsules had strong
expression of TERT; as the concentration of AR-12 increased, the expression of TERT decreased. B: 2.5 µM AR-12; C: 5.0 µM AR-12; D:
7.5 µM AR-12. Scale bar in all images is equal to 30 µm.
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2211have been successful in vitro but failed clinically due to their
toxic effects on the corneal endothelium and other cell types.
Other  intraocular  cell  types,  including  the  corneal
endothelium, express pAkt, suggesting that its inhibition may
cause corneal edema. However, preliminary data from our
laboratory  indicate  that  AR-12  is  not  toxic  to  corneal
endothelial  cells  when  cells  were  continually  exposed  by
intracameral infusion for 10 min at a concentration of 20 µM
as  determined  by  cell  morphology  and  the  absence  of
caspase-3  staining.  Therefore,  we  believe  that  the  use  of
AR-12 intraoperatively or by impregnation of an IOL, may be
safe and effective in inhibiting PCO. Further studies are in
progress to evaluate the minimal exposure time necessary for
effective PCO inhibition.
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